Literature DB >> 16328092

Long-term treatment of antiphospholipid syndrome-associated cerebral arterial thromboses with intravenous immunoglobulin: a case report.

B Arabshahi1, E D Thompson, E M Smergel, D P Goldsmith.   

Abstract

We report a now 13-year-old male with trisomy 21, hypothyroidism, and insulin-dependent diabetes who developed acute hemiplegia due to the antiphospholipid antibody syndrome (APS) at age four. The risks of long-term anticoagulation were initially considered to be high; hence, he was treated with monthly infusions of intravenous immunoglobulin (IVIG) at 2 g/kg for 2 years and then every other month for 7 years. Antiphospholipid antibodies were no longer detectable within 6 months and have continued to be negative. There was no clinical deterioration or further changes on magnetic resonance arteriography over 7 years. IVIG may be an alternative therapeutic choice for children with APS who are not candidates for conventional anticoagulation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16328092     DOI: 10.1007/s10067-005-0127-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  18 in total

Review 1.  The antiphospholipid syndrome.

Authors:  Jerrold S Levine; D Ware Branch; Joyce Rauch
Journal:  N Engl J Med       Date:  2002-03-07       Impact factor: 91.245

2.  Moyamoya, dystonia during hyperventilation, and antiphospholipid antibodies.

Authors:  Tarif Bakdash; Alan R Cohen; Joanne M Hempel; Jason Hoagland; Arthur J Newman
Journal:  Pediatr Neurol       Date:  2002-02       Impact factor: 3.372

3.  Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children.

Authors:  G Kenet; S Sadetzki; H Murad; U Martinowitz; N Rosenberg; S Gitel; G Rechavi; A Inbal
Journal:  Stroke       Date:  2000-06       Impact factor: 7.914

4.  Intravenous immunoglobulin and antiphospholipid syndrome: comment on the article by Erkan et al.

Authors:  R Jean; E Bastard; E Cretel; P Lefèvre; J M Durand
Journal:  Arthritis Rheum       Date:  2004-08

5.  Clinical significance of lupus anticoagulants in children.

Authors:  C Male; K Lechner; S Eichinger; P A Kyrle; S Kapiotis; H Wank; A Kaider; I Pabinger
Journal:  J Pediatr       Date:  1999-02       Impact factor: 4.406

6.  Identification of an Fc gamma receptor-independent mechanism by which intravenous immunoglobulin ameliorates antiphospholipid antibody-induced thrombogenic phenotype.

Authors:  S S Pierangeli; R Espinola; X Liu; E N Harris; J E Salmon
Journal:  Arthritis Rheum       Date:  2001-04

Review 7.  Management of thrombosis in antiphospholipid antibody syndrome.

Authors:  M Petri
Journal:  Rheum Dis Clin North Am       Date:  2001-08       Impact factor: 2.670

Review 8.  Recent advances in antiphospholipid antibodies and antiphospholipid syndromes in pediatric populations.

Authors:  T Avcin; R Cimaz; P L Meroni
Journal:  Lupus       Date:  2002       Impact factor: 2.911

Review 9.  The role of IVIG in the management of patients with antiphospholipid antibodies and recurrent pregnancy losses.

Authors:  A Parke
Journal:  Clin Rev Allergy       Date:  1992 Spring-Summer

10.  Antiphospholipid antibodies in cerebrovascular ischemia and stroke in childhood.

Authors:  M Schöning; R Klein; I Krägeloh-Mann; M Falck; S Bien; P A Berg; R Michaelis
Journal:  Neuropediatrics       Date:  1994-02       Impact factor: 1.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.